"
Cell therapy of a patient with type III osteogenesis imperfecta caused by mutation in COL1A2 gene and unstable collagen type I"
written by Marcin Majka, Magdalena Janeczko, Jolanta Goździk, Danuta Jarocha, Aleksandra Auguściak-Duma, Joanna Witecka, Marta Lesiak, Halina Koryciak-Komarska, Aleksander L. Sieroń, Jacek Józef Pietrzyk,
published by
Open Journal of Genetics,
Vol.3 No.1, 2013
has been cited by the following article(s):
|
[1]
|
Comprehensive Review of Osteogenesis Imperfecta: Current Treatments and Future Innovations
Human Gene Therapy,
2025
DOI:10.1089/hum.2024.191
|
|
|
|
|
[2]
|
Analysis of the TID-I and TID-L Splice Variants’ Expression Profile under In Vitro Differentiation of Human Mesenchymal Bone Marrow Cells into Osteoblasts
Cells,
2024
DOI:10.3390/cells13121021
|
|
|
|
|
[3]
|
Analysis of miRNAs in Osteogenesis imperfecta Caused by Mutations in COL1A1 and COL1A2: Insights into Molecular Mechanisms and Potential Therapeutic Targets
Pharmaceuticals,
2023
DOI:10.3390/ph16101414
|
|
|
|
|
[4]
|
Curative Cell and Gene Therapy for Osteogenesis Imperfecta
Journal of Bone and Mineral Research,
2022
DOI:10.1002/jbmr.4549
|
|
|
|
|
[5]
|
Osteogenesis Imperfecta: Current and Prospective Therapies
Biomolecules,
2021
DOI:10.3390/biom11101493
|
|
|
|
|
[6]
|
Osteogenesis Imperfecta: Current and Prospective Therapies
Biomolecules,
2021
DOI:10.3390/biom11101493
|
|
|
|
|
[7]
|
Curative Cell and Gene Therapy for Osteogenesis Imperfecta
Journal of Bone and Mineral Research,
2020
DOI:10.1002/jbmr.4549
|
|
|
|